Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant,...
Pharmaceutical
Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age...
Samsung Bioepis and Biogen Receive Positive CHMP Opinion for Aflibercept Biosimilar, OPUVIZ™
OPUVIZ™, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for marketing authorization...
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared...
Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old...
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws’ Further Transformation and Growth Director James J Marino Also to...
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal...
213,285 Orion Corporation A shares converted into B shares
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE20 SEPTEMBER 2024 at 9.30...
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
ROCKVILLE, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and...
ADR Ratio Change
September 19, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical...
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering
WALTHAM, Mass., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed...
GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update
Cash and cash equivalents totaled €61.6 million as of June 30, 2024, excluding the €48.7 million milestone invoiced in June...
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
FDA lifts partial clinical holds on ersodetug for the treatment of congenital HI; Phase 3 sunRIZE study to proceed in...
Anju to Highlight Newly Launched MA Knowledge at DIA MICC 2024 in London
CHICAGO, Sept. 19, 2024 /PRNewswire/ -- Anju, a leading provider of adaptive life sciences software solutions, is pleased to announce its...
Aytu BioPharma to Report Fiscal 2024 Full Year and Fourth Quarter Operational and Financial Results on September 26, 2024
DENVER, CO / ACCESSWIRE / September 19, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company...
Theralase(R) Extends Warrants
TORONTO, ON / ACCESSWIRE / September 19, 2024 / Theralase® Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion
CHICAGO, IL / ACCESSWIRE / September 19, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
Prendio-BioProcure Strengthens Leadership Team with Four Strategic Appointments, Accelerating Innovation and Growth
BURLINGTON, Mass., Sept. 19, 2024 /PRNewswire/ -- Prendio-BioProcure, a leader in procurement solutions for the life sciences industry, is thrilled...
Autoradiography Films Market to Reach $174.9 Million, Globally, by 2033 at 3% CAGR: Allied Market Research
Increase in prevalence of chronic diseases, surge in technological advancements, and rise in R&D activities in the healthcare sector are...